[Skip to Navigation]
Sign In
JAMA Clinical Guidelines Synopsis
August 8, 2022

Treatment of Clostridioides difficile Infection

Author Affiliations
  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
  • 2Department of Internal Medicine, University of Chicago, Chicago, Illinois
JAMA. 2022;328(9):881-882. doi:10.1001/jama.2022.12251

Clostridioides difficile infection is a common nosocomial and community-acquired cause of diarrhea, with an estimated 453 000 cases per year in the United States.1 Treatment of CDI is based on severity and recurrence risk.

The ACG funded the guideline and commissioned experts in the management of CDI, who collaborated with the ACG’s Practice Parameters Committee (Table). The panel disclosed potential conflicts of interest (recusal was not required). The quality of evidence and strength of recommendations were evaluated using GRADE methodology.1

Add or change institution